The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Novo Nordisk markets its blockbuster semaglutide (GLP-1) medicines as Ozempic pre-filled pens and Rybelsus oral ... The study found that the drug was not associated with a risk of adverse ...
consistent with CagriSema’s broader class of GLP-1 receptor agonist drugs. Novo declined to comment for this story as it is in the regulatory quiet period ahead of quarterly results on Wednesday.
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results